Cardiac safety biomarkers
Biomarkers of cardiac and drug-induced injury will be discussed by the FDA Pharmaceutical Science Advisory Committee/Nonclinical Studies Subcommittee Sept. 9-10. The subcommittee will consider reports from its expert working groups: the cardiotoxicity biomarker working group is preparing a position paper recommending the use of cardiac troponins as a biomarker of cardiac injury (1"The Pink Sheet" Nov. 19, 2001, p. 8). Potential transfer of oversight of the subcommittee to the National Center for Toxicological Research's Science Advisory Board will also be revisited at the meeting. The meeting will be at 5630 Fishers Lane, Rockville, Md., at 1:30 p.m. on Sept. 9 and 8 a.m. on Sept. 10...
You may also be interested in...
FDA's cardiotoxicity biomarker working group is preparing a position paper recommending the use of cardiac troponins as a biomarker of cardiac injury
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.